Company: RGBP
Filing Date: 2025-05-16
Form Type: 10-Q
Source: 0001641172-25-011206
Chunk: 21

Company: Regen BioPharma Inc
Filing Date: 2025-05-16
Form: 10-Q
Item: Part I, Item 1
Chunk 21
---
 provided in this
Quarterly report on Form 10Q may contain forward-looking statements within the meaning of Section 21E or Securities Exchange Act of 1934
that are not historical facts and information. These statements represent the Company’s expectations or beliefs, including, but
not limited to, statements concerning future and operating results, statements concerning industry performance, the Company’s operations,
economic performance, financial conditions, margins and growth in sales of the Company’s products, capital expenditures, financing
needs, as well assumptions related to the forgoing. For this purpose, any statements contained in this Quarterly Report that are not statement
of historical fact may be deemed to be forward-looking statements. These forward-looking statements are based on current expectations
and involve various risks and uncertainties that could cause actual results and outcomes for future periods to differ materially from
any forward-looking statement or views expressed herein. The Company’s financial performance and the forward-looking statements
contained herein are further qualified by other risks including those set forth from time to time in the documents filed by the Company
with the Securities and Exchange Commission. All references to” We”, “ Us”, “ Company” or the “ Company”
refer to Regen BioPharma, Inc.

Results of Operations

Three month ended December 31, 2024 and 2023

Revenues

Revenues from continuing
operations were $59,065 for the three months ended December 31, 2024 and $59,065 for the same period ended 2023. $27,425 of revenue from
related parties recognized during the three months ended December 31, 2024 and December 31, 2023 consisted of anniversary expense receivable
pursuant to a license granted by the Company to Zander Therapeutics, Inc. and $31,640 of revenue recognized during both of the three months
ended December 31, 2024 and 2023 were recognized pursuant to licenses granted to Oncology Pharma, Inc.

Operating Expenses

Operating Expense were $120,443
for the three months ended December 31, 2024 and $ 181,847for the same period ended 2023. The primarily operating expense for 2024 consists
of $ 84,626 to Consulting & Professional expenses and $ 22,500 in rent. In the same period in previous year Consulting and Professional
fees expenditure were $106,900 During the period ended 2023 research and development expenses amounted to $47,528 constituting the second
larg